N2OFF shares surge 18.79% intraday after MitoCareX Bio reported in vitro results showing MITOLINE™'s anti-inflammatory potential for a $1200B market and identified a space flight biomarker for precision oncology.

N2OFF surged 18.79% in intraday trading, with its subsidiary MitoCareX Bio announcing promising results from in vitro experiments showing its MITOLINE™ platform-derived small molecule candidates reduce key inflammatory markers in human immune cells, supporting further in vivo validation and lead optimization for inflammatory metabolic diseases—a market projected to exceed $120 billion by 2030. Additionally, MitoCareX Bio identified the SLC25A mitochondrial carrier as a potential biomarker for space flight-induced dysfunction, leveraging NASA data and focusing on the ADP/ATP carrier AAC3 to advance precision oncology.